Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish ...

Novo Nordisk’s (NVO) (OTCPK:NONOF) contract with Swiss medical device maker Ypsomed (OTCPK:YPHDF) includes a deal to supply ...

Now, a partnership between Ypsomed and Sidekick Heath aims to tackle that problem. Ypsomed is a top developer of injection and infusion systems, so knows a lot about the difficulties that patients ...

If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. To calculate this metric for Ypsomed Holding, this is the ...

Ypsomed Holding (SWX:YPSN) has recently announced a strategic partnership with Astria Therapeutics to develop an autoinjector for STAR-0215, underscoring its commitment to innovation and enhancing ...

Medical technology manufacturer plans to divest diabetes products business / Focus on injection systems © 2001-2024 Plasteurope.com | Imprint | Privacy | Cookie settings ...

Novo Nordisk’s (NVO) (OTCPK:NONOF) contract with Swiss medical device maker Ypsomed (OTCPK:YPHDF) includes a deal to supply injection pens for Danish drugmaker’s next-gen obesity therapy ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

0.13 = CHF87m ÷ (CHF1.2b - CHF513m) (Based on the trailing twelve months to September 2024). So, Ypsomed Holding has an ROCE of 13%. That's a pretty standard return and it's in line with the industry ...